论文部分内容阅读
目的探讨分析氨氯地平阿托伐他汀钙片治疗高血压并高血脂的临床疗效。方法 60例高血压并高血脂患者作为研究对象,按照治疗方法不同分为观察组与对照组,各30例。观察组给予氨氯地平阿托伐他汀钙片治疗,对照组给予阿托伐他汀钙片治疗,对比分析两组患者治疗前后的血压、血脂情况及不良反应发生率。结果两组患者治疗前血压水平比较,差异无统计学意义(P>0.05)。两组治疗后血压水平均有所改善,观察组血压改善情况明显优于对照组,差异具有统计学意义(P<0.05)。两组患者治疗前血脂水平比较,差异无统计学意义(P>0.05)。两组治疗后血脂水平均有所改善,观察组血脂改善情况明显优于对照组,差异具有统计学意义(P<0.05)。观察组不良反应发生率(3.3%)明显低于对照组(20.0%),差异具有统计学意义(P<0.05)。结论氨氯地平阿托伐他汀钙片治疗高血压合并高血脂的疗效显著,安全性较高,不良反应较少,值得临床推广应用。
Objective To investigate the clinical efficacy of amlodipine atorvastatin calcium in the treatment of hypertension and hyperlipidemia. Methods Sixty patients with hypertension and hyperlipemia were divided into observation group and control group with 30 cases in each group according to different treatment methods. The observation group was given amlodipine atorvastatin calcium tablets, while the control group was given atorvastatin calcium tablets. The blood pressure, blood lipids and the incidence of adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in blood pressure level between the two groups before treatment (P> 0.05). The blood pressure of both groups improved after treatment, and the improvement of blood pressure in the observation group was better than that of the control group (P <0.05). There was no significant difference in serum lipids between the two groups before treatment (P> 0.05). The blood lipid levels of both groups improved after treatment. The improvement of blood lipid in the observation group was significantly better than that of the control group, with significant difference (P <0.05). The incidence of adverse reactions in the observation group (3.3%) was significantly lower than that in the control group (20.0%), the difference was statistically significant (P <0.05). Conclusion Amlodipine atorvastatin calcium treatment of hypertension with hyperlipidemia significant effect, high safety, fewer adverse reactions, it is worth promoting the clinical application.